Apixaban (Eliquis) Evidence‑Based Recommendations

Stroke Prevention in Non‑valvular Atrial Fibrillation

In the ARISTOTLE randomized trial, apixaban 5 mg twice daily was superior to warfarin, reducing stroke or systemic embolism by 21 %, major bleeding by 31 %, and all‑cause mortality by 11 % (high‑quality RCT)【1】.
The AVERROES trial showed that, in patients unsuitable for warfarin, apixaban lowered stroke or systemic embolism by 55 % compared with aspirin (1.6 %/yr vs 3.7 %/yr) with comparable major‑bleeding rates (high‑quality RCT)【2】.
Dose reduction to 2.5 mg twice daily is recommended when a patient meets any two of the following: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL (based on pharmacologic studies)【3】.
Apixaban markedly decreases intracranial hemorrhage (0.24 %/yr) versus warfarin (0.47 %/yr) while preserving similar protection against ischemic stroke (high‑quality RCT)【1】.

The AMPLIFY trial demonstrated non‑inferiority of apixaban for acute DVT treatment, with recurrent VTE or VTE‑related death of 2.3 % versus 2.7 % with enoxaparin/warfarin (RR 0.84) and a significantly lower major‑bleeding rate (0.6 % vs 1.8 %) (high‑quality RCT)【4】.
In the same trial for acute PE, apixaban yielded similar PE event rates (1.0 % vs 0.9 % with enoxaparin/warfarin) but reduced the composite of major or clinically relevant non‑major bleeding (4.3 % vs 9.7 %) (high‑quality RCT)【4】.

AMPLIFY‑EXT showed that after 6–12 months of initial therapy, apixaban 2.5 mg twice daily reduced recurrent VTE or all‑cause mortality to 3.8 % (vs 8.8 % with placebo), and the 5 mg twice‑daily regimen reduced it to 4.2 % (high‑quality RCT)【5】.
Major‑bleeding rates were low and comparable across groups (placebo 0.5 %, apixaban 2.5 mg 0.2 %, apixaban 5 mg 0.1 %) (high‑quality RCT)【5】.

CrCl > 50 mL/min – standard apixaban dosing applies for all indications (clinical pharmacology guidance)【6】.
CrCl 15–50 mL/min – dose‑reduction criteria (age ≥ 80 yr, weight ≤ 60 kg, serum creatinine ≥ 1.5 mg/dL) are applied only for atrial‑fibrillation; standard dosing is retained for VTE treatment (clinical pharmacology guidance)【6】.
CrCl < 15 mL/min or dialysis – apixaban may be used for atrial‑fibrillation (5 mg or 2.5 mg twice daily based on other criteria), but evidence is limited (expert consensus)【6】.

Apixaban is contraindicated in patients with prosthetic heart valves or valvular atrial fibrillation (e.g., moderate‑to‑severe mitral stenosis) (regulatory guidance)【7】【8】.
The black‑box warning emphasizes that abrupt discontinuation increases stroke risk; bridging anticoagulation should be considered unless contraindicated due to bleeding (regulatory warning)【1】.

Standard dose (5 mg twice daily) is a Class I, Level B recommendation as an alternative to warfarin for most patients with non‑valvular atrial fibrillation who have at least one additional stroke‑risk factor. 9, 10
Dose reduction to 2.5 mg twice daily is indicated when a patient meets ≥ two of the following criteria: age ≥ 80 years, body weight ≤ 60 kg, serum creatinine ≥ 1.5 mg/dL. This reduction applies specifically to the atrial‑fibrillation indication. 9, 11

In patients unsuitable for vitamin K antagonists, apixaban 5 mg twice daily is superior to aspirin for preventing stroke or systemic embolism in non‑valvular atrial fibrillation when the patient has ≤ 1 dose‑reduction criterion. 9, 12
The number needed to treat is 48 patients to prevent one stroke or systemic embolism. 12, 13
Apixaban 2.5 mg twice daily may be considered (Class IIb, Level C) for warfarin‑unsuitable patients who meet ≥ two dose‑reduction criteria. 9, 12

At least one of the following risk factors must be present to qualify for apixaban therapy: age ≥ 75 years, prior stroke/TIA/systemic embolism, symptomatic heart failure within 3 months or left‑ventricular ejection fraction ≤ 40 %, diabetes mellitus, hypertension requiring pharmacologic treatment. These criteria define the minimum stroke‑risk burden for initiation. 11, 12

Apixaban has no absolute contraindication in patients with severe renal impairment (creatinine clearance < 15 mL/min or on dialysis) for the atrial‑fibrillation indication, unlike dabigatran. 9

Routine coagulation monitoring is not required; however, missed doses quickly increase thrombotic risk because of apixaban’s short half‑life. 10, 11
Concurrent use of apixaban with antiplatelet agents has not been established as safe or effective (Class IIb, Level C). 9, 12
At the time of the 2012 guidelines, no specific antidote was available for emergency reversal of apixaban. 10, 11